Little Journey, a pioneer in pediatric care, receives £6 million in Series A funding to revolutionize global pediatric healthcare.
- Led by Par Equity, the investment will aid the company’s expansion into the US market, enhancing their global reach.
- Additional backing from Mercia Ventures and other notable investors strengthens Little Journey’s mission.
- The funding will enable product development and improve data-focused healthcare management.
- Chris Evans and Sophie Copley are set to advance pediatric care with an emphasis on patient and family engagement.
Little Journey is spearheading innovations in pediatric healthcare, having secured £6 million in Series A funding. This capital influx aims to enhance their mission of transforming pediatric care worldwide. The funding round, led by Par Equity, underscores confidence in Little Journey’s pioneering approach to psychological support for children.
Investors including Mercia Ventures, the Northern Powerhouse Investment Fund, Octopus Ventures, Calm/Storm Ventures, as well as several angel investors, have contributed to this funding round. Their combined support is expected to bolster Little Journey’s expansion efforts, primarily focusing on the US healthcare market.
With the new investment, Little Journey plans to scale its operations, reaching more children and families globally. They have identified critical improvements such as enhancing their product’s content scalability, interoperability, and data collection capabilities. These features are crucial for adopting data-focused and patient-centric healthcare approaches.
The company, co-founded by Chris Evans and Sophie Copley in 2018, has evolved to meet the needs of pediatric patients. Evans’ personal experiences as an anesthetic doctor and father have informed Little Journey’s approach to easing the burden of pediatric clinical trials, which often suffer from low recruitment and adherence rates.
Sophie Copley highlighted the potential for new funding to enhance Little Journey’s capabilities. The company already customizes support by patient age, language, procedure, and trial protocol. This funding will allow them to further globalize their services, fostering a more data-driven, personalized model of pediatric care.
The journey of Little Journey has seen rapid growth, reaching thousands of young patients in over 100 hospitals across 11 countries. Their vast repository, available in 20 languages, supports various medical procedures and emphasizes partnerships with global pharmaceutical players, thereby enhancing pediatric clinical trial experiences.
Investors like Par Equity are instrumental in shaping Little Journey’s future, helping craft strategies that are essential for thriving in the US market. Their expertise in scaling growth companies enhances Little Journey’s efforts to innovate pediatric care significantly.
Elizabeth Young of Par Equity emphasized that investing in healthtech is integral to their mission, particularly with technologies like Little Journey, which cater specifically to pediatric needs. Little Journey’s association with the LEGO Foundation contributes additional grant funding for enhancing accessibility and creating solutions for neurodivergent children.
With robust investment and strategic partnerships, Little Journey is poised to transform pediatric healthcare globally.
